$4.85
+9.5%LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
LFMD โข NASDAQ
| LifeMD, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||
194.1M | 212.5M | 152.5M | 119M | 92.9M | 37.3M | 12.5M | 8.3M | 5.1M | 5.2M | 1.2M | 714.2K | 808.4K | 673.8K | 743.8K | |
GROSS PROFIT | |||||||||||||||
(39.3M) | (24.1M) | (18.9M) | (18.7M) | (18M) | (8.9M) | (3.3M) | (2M) | (1.5M) | (1.9M) | (247.8K) | (172.9K) | (181.3K) | (125.6K) | (241.3K) | |
154.8M | 188.4M | 133.6M | 100.4M | 74.9M | 28.4M | 9.2M | 6.4M | 3.6M | 3.3M | 971.1K | 541.3K | 627.1K | 548.2K | 502.6K | |
OPERATING INCOME | |||||||||||||||
(162.4M) | (204.5M) | (148.1M) | (143.8M) | (129.2M) | (86.3M) | (12.1M) | (8.4M) | (4.6M) | (4.5M) | (1.2M) | (1.1M) | (1.2M) | (1.1M) | (1.1M) | |
(144M) | (175.7M) | (128.1M) | (125.3M) | (122.1M) | (84M) | (10.6M) | (8.4M) | (4.6M) | (4.5M) | (1.2M) | (1.1M) | (1.2M) | (1.1M) | (1.1M) | |
(7.3M) | (9.5M) | (6.1M) | (3M) | (948.2K) | (446.7K) | (222.9K) | (120.5K) | (0.0) | (0.0) | (23.9K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-7.7M | -16.1M | -14.5M | -43.4M | -54.3M | -57.8M | -2.9M | -2.1M | -1.1M | -1.2M | -262.2K | -530.9K | -546.4K | -540K | -576.4K | |
PRE-TAX INCOME | |||||||||||||||
(1.4M) | (2.2M) | (2.6M) | (1.3M) | (3M) | (1.7M) | (761.2K) | (354.4K) | (100.5K) | (48.6K) | (37.5K) | (4.7K) | (3.4K) | (3.4K) | (21.3K) | |
-1.4M | -2.2M | -2.6M | -1.3M | -3M | -1.7M | -761.2K | -354.4K | -100.5K | -48.6K | -37.5K | -4.7K | -3.4K | -3.4K | -21.3K | |
(11.1M) | (19.3M) | (13.9M) | (15.5M) | (6.2M) | (1.8M) | (1.3M) | -517K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-2.5M | -2.2M | -2.9M | -1.2M | -7M | -2.6M | -761.2K | -354.4K | -150.9K | -48.6K | 89.8K | 53.2K | 260.9K | 77.2K | 56.2K | |
-10.2M | -18.3M | -17.4M | -44.7M | -61.3M | -60.4M | -3.7M | -1.5M | -1.2M | -1.2M | -172.4K | -477.7K | -285.5K | -462.8K | -520.1K | |
NET INCOME | |||||||||||||||
(45.7K) | (402K) | (428K) | (360.7K) | (7.7K) | (122.5K) | -122.5K | -124.7K | -12.5K | (0.0) | -13.2K | -17.2K | -17.2K | -17.2K | -17.2K | |
-7.1M | -18.9M | -20.6M | -45.5M | -60.9M | -58.6M | -3.5M | -1.2M | -1.2M | -1.1M | -62K | -460.5K | -268.3K | -445.6K | -502.9K |
LFMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 02, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 17, 2025 | November 17, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 17, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 |
Continue your LFMD research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.